Itron, Inc. (NASDAQ:ITRI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Itron, Inc. (NASDAQ:ITRI) has been given an average recommendation of “Moderate Buy” by the fourteen analysts that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $139.00.

A number of research firms have weighed in on ITRI. Baird R W cut shares of Itron from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Wall Street Zen downgraded Itron from a “buy” rating to a “hold” rating in a research report on Monday, December 29th. Weiss Ratings reissued a “buy (b-)” rating on shares of Itron in a report on Monday, December 29th. Robert W. Baird reaffirmed a “neutral” rating and set a $118.00 target price (down from $137.00) on shares of Itron in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. increased their target price on Itron from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th.

Itron Stock Performance

Shares of ITRI stock opened at $94.47 on Monday. Itron has a 52-week low of $90.11 and a 52-week high of $142.00. The company has a quick ratio of 1.91, a current ratio of 2.17 and a debt-to-equity ratio of 0.46. The stock has a market cap of $4.33 billion, a PE ratio of 16.99, a price-to-earnings-growth ratio of 0.53 and a beta of 1.49. The business has a 50-day simple moving average of $100.51 and a 200-day simple moving average of $118.27.

Itron (NASDAQ:ITRI) last announced its quarterly earnings results on Thursday, October 30th. The scientific and technical instruments company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.06. The company had revenue of $581.63 million during the quarter, compared to analysts’ expectations of $578.49 million. Itron had a return on equity of 17.82% and a net margin of 10.69%.Itron’s quarterly revenue was down 5.5% on a year-over-year basis. During the same period last year, the business earned $1.84 earnings per share. Itron has set its FY 2025 guidance at 6.840-6.940 EPS and its Q4 2025 guidance at 2.150-2.250 EPS. On average, equities analysts expect that Itron will post 5.33 EPS for the current year.

Insiders Place Their Bets

In related news, SVP John F. Marcolini sold 553 shares of Itron stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $96.51, for a total value of $53,370.03. Following the sale, the senior vice president directly owned 13,843 shares in the company, valued at approximately $1,335,987.93. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Justin K. Patrick sold 379 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $96.51, for a total value of $36,577.29. Following the sale, the senior vice president owned 20,382 shares of the company’s stock, valued at approximately $1,967,066.82. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 2,971 shares of company stock valued at $286,731. 1.51% of the stock is owned by company insiders.

Institutional Trading of Itron

Institutional investors have recently made changes to their positions in the company. Impax Asset Management Group plc boosted its position in Itron by 127.3% during the third quarter. Impax Asset Management Group plc now owns 1,588,950 shares of the scientific and technical instruments company’s stock worth $197,153,000 after acquiring an additional 890,040 shares during the last quarter. Norges Bank purchased a new position in Itron in the 2nd quarter worth approximately $71,727,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Itron by 129.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 732,274 shares of the scientific and technical instruments company’s stock worth $76,713,000 after purchasing an additional 413,487 shares during the last quarter. Merewether Investment Management LP grew its position in shares of Itron by 1,552.7% in the second quarter. Merewether Investment Management LP now owns 300,787 shares of the scientific and technical instruments company’s stock valued at $39,593,000 after purchasing an additional 282,587 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Itron by 42.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 604,580 shares of the scientific and technical instruments company’s stock valued at $75,306,000 after purchasing an additional 180,366 shares during the last quarter. 96.19% of the stock is owned by institutional investors and hedge funds.

Itron Company Profile

Itron, Inc (NASDAQ: ITRI) is a global technology company that develops innovative solutions to measure, manage and analyze the use of energy and water. Its comprehensive portfolio includes smart meters, data collection devices, communication networks and advanced software applications designed to optimize utility operations and foster sustainable resource management. The company’s offerings enable utilities and cities to accurately monitor consumption patterns, streamline billing processes and improve grid reliability.

Itron’s product lineup spans a range of hardware and software solutions, from residential and commercial smart meters to meter data management systems (MDMS), networked communication platforms and analytics tools.